Fracture risk prediction with FRAX in Slovak postmenopausal women

• Autorzy: Eva Némethová , Zdenko Killinger , Juraj Payer
• Języki publikacji: EN

Abstrakty

EN

Słowa kluczowe

EN

Osteoporosis; Fracture risk; FRAX; Treatment thresholds

• Czasopismo: Open Medicine
• Rocznik: 2013
• Tom: 8
• Numer: 5
• Strony: 571-576

Daty

wydano

2013-10-01

online

2013-09-18

Twórcy

autor

Eva Némethová

• 5th Department of Internal Medicine, Faculty of Medicine Comenius University and University Hospital Ružinov, Bratislava, 82606, Slovakia,

autor

Zdenko Killinger

• 5th Department of Internal Medicine, Faculty of Medicine Comenius University and University Hospital Ružinov, Bratislava, 82606, Slovakia

autor

Juraj Payer

• 5th Department of Internal Medicine, Faculty of Medicine Comenius University and University Hospital Ružinov, Bratislava, 82606, Slovakia

Bibliografia

• [1] Kanis J.A., McCloskey E.V., Johansson H., Cooper C., Rizzoli R., Reginster J.Y., et al., European guideance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos Int, 2013, 24(1), 23–57 http://dx.doi.org/10.1007/s00198-012-2074-y[Crossref]
• [2] Magaziner J., Simonsick E.M., Kashner T.M., Hebel J.R., Kenzora J.E., Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study, J Gerontol, 1990, 45(3), M101–107 http://dx.doi.org/10.1093/geronj/45.3.M101[Crossref]
• [3] Payer J., Killinger Z., et al., Osteoporóza, Herba, Bratislava 2012
• [4] National Osteoporosis Foundation, Clinician’s Guide to Prevention and Treatment of Osteoporosis, Washington, DC: National Osteoporosis Foundation, 2010
• [5] McCloskey E.V., Johansson H., Oden A., Kanis J.A., Fracture risk assesment, Clinical Biochemistry, 2012,45, 887–893 http://dx.doi.org/10.1016/j.clinbiochem.2012.05.001[Crossref][WoS]
• [6] Kanis J.A., Hans D., Cooper C., Baim S., Bilezikian J.P., Binkley N., et al., Interpretation and use of FRAX in clinical practice. Osteoporos Int, 2011, 22, 2395–2411 http://dx.doi.org/10.1007/s00198-011-1713-z[Crossref]
• [7] Gehlbach S.H., Bigelow C., Heimisdottir M., May S., Walker M., Kirkwood J.R., Recognition of vertebral fracture in a clinical setting, Osteoporos Int, 2000, 11(7), 577–582 http://dx.doi.org/10.1007/s001980070078[Crossref]
• [8] Hans D.B., Kanis J.A., Baim S., Bilezikian J.P., Binkley N., Cauley J.A., et al., Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX, Journal of Clinical Densitometry: Assessment of Skeletal Health, 2011, 14(3), 171–180 http://dx.doi.org/10.1016/j.jocd.2011.05.007[WoS][Crossref]
• [9] Sornay-Rendu E., Munoz F., Delmas P.D., Chapurlat RD., The FRAX tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort? J Bone Miner Res, 2010, 25, 2101–2107 http://dx.doi.org/10.1002/jbmr.106[WoS][Crossref]
• [10] González-Macías J., Marin F., Vila J., Díez-Pérez A., Probability of fractures predicted by FRAX and observed incidence in the Spanish ECOSAP study cohort, Bone 2012, 50(1), 373–377 http://dx.doi.org/10.1016/j.bone.2011.11.006[Crossref][WoS]
• [11] Fraser L.A., Langsetmo L., Berger C., Ioannidis G., Goltzman D., Adachi J.D., et al, Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos, Osteoporos Int, 22, 829–837
• [12] Tremollieres F.A., Pouillés J.M., Drewniak N., Laparra J., Ribot C.A., Fargent-Molina P., Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool, J Bone Miner Res, 2010, 25(5), 1002–1009 http://dx.doi.org/10.1002/jbmr.12[Crossref]
• [13] Aubry-Rozier B., Stoll D., Krieg M.A., Lamy O., Hans D., What was your fracture risk evaluated by FRAX the day before your osteoporotic fracture?, Clin Rheumatol, 2013, 32(2), 219–223 http://dx.doi.org/10.1007/s10067-012-2106-1[Crossref][WoS]
• [14] Ensrud K.E., Lui L.Y., Taylor B.C., Schousboe J.T., Donaldson M.G., Fink H.A., et al., A comparison of prediction models for fractures in older women: is more better?, Arch Int Med, 2009, 169(22), 2087–2094 http://dx.doi.org/10.1001/archinternmed.2009.404[Crossref]
• [15] Donaldson M.G., Palermo L., Schousboe J.T., Ensrud K.E., Hochberg M.C., Cummings S.R., FRAX and risk of vertebral fractures: The fracture intervention trial, Journal of Bone and Mineral Research, 2009, 24(11), 1793–1799 http://dx.doi.org/10.1359/jbmr.090511[Crossref]
• [16] Pluskiewicz W., Adamczyk P., Franek E., Leszczynski P., Sewerynek E., Wirchowska H., et al, Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX and nomogram by Nguyen et al.-Conformity between methods and their clinical utility, Bone 2010,46(6),1661–1667 http://dx.doi.org/10.1016/j.bone.2010.02.012[WoS][Crossref]
• [17] Cummins N.M., Poku E.K., Towler M.R., O’Driscoll O.M., Ralston S.H., Clinical Risk Factors for Osteoporosis in Ireland and the UK: A Comparison of FRAX and QFractureScores, Calcif Tissue Int, 2011, 89,172–177 http://dx.doi.org/10.1007/s00223-011-9504-2[WoS][Crossref]
• [18] Waris V.J., Sirola J.P., Kiviniemi V.V., Tuppurainen M.T., Waris V.P., Mikkeli Osteoporosis Index Identifies Fracture Risk Factors and Osteoporosis and Intervention Thresholds Parallel with FRAX, Journal of Osteoporosis, 2011, 2011, ID 732560, 7 pages doi:10.4061/2011/732560 [Crossref]
• [19] McCloskey E., Johansson H., Oden A., Kanis J.A., Fracture risk assessment, Clinical Biochemistry, 2012, 46, 887–893 http://dx.doi.org/10.1016/j.clinbiochem.2012.05.001[Crossref][WoS]
• [20] Poku E.K., Towler M.R., Cummins N.M., Newman J.D., Developing Novel Prognostic Biomarkers for Multivariate Fracture Risk Prediction Algortihms Calcif Tissue Int 2012,91,204–214
• [21] Collins G.S., Michaelsson K., Fracture risk assessment: state of the art, methodologically unsound, or poorly reported?, Curr Osteoporos Rep, 2012,10,199–207 http://dx.doi.org/10.1007/s11914-012-0108-1[WoS][Crossref]
• [22] Lippuner K., Johansson H., Borgstrom F., Kanis J.A., Rizzoli R., Cost-effective intervention thresholds against osteoporotic fractures based on FRAX in Switzerland, Osteoporosis Int, 2012, 23, 2579–2589 http://dx.doi.org/10.1007/s00198-011-1869-6[Crossref][WoS]
• [23] Compston J., Cooper A., Cooper C., Francis R., Kanis J.A., Marsch D., et al., Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from age of 50 years in the UK, Maturitas, 2009, 62(2), 105–108 http://dx.doi.org/10.1016/j.maturitas.2008.11.022[Crossref][WoS]
• [24] Johansson H., Kanis J.A., McCloskey E.V., Oden A., Devogelaer J.-P., Kaufman J.M, et al., A FRAX model for the assessment of fracture probability in Belgium, Osteoporosis Int, 2011, 22, 453–461 http://dx.doi.org/10.1007/s00198-010-1218-1[Crossref]
• [25] Fujiwara S., Nakamura T., Orimo H., Hosoi T., Gorai I., Oden A., et al., Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX), Osteoporosis Int, 2008, 19, 429–435 http://dx.doi.org/10.1007/s00198-007-0544-4[WoS][Crossref]
• [26] Socialstyrelsen, rörelseorganens sjukdomar 2012 Osteoporos, artros, inflammatorisk ryggsjukdom och ankyloserande spondylit, psoriasisartrit och reumatoid artrit Stöd för styrning och ledning. Socialstyrelsen/Iwa Wasberg, 2012
• [27] Braun J., Pfeilschifter J., Leitliniengerechte Diagnostik und Therapie der Osteoporose 2010, Z Rheumatol, 2010, 69, 327–339 http://dx.doi.org/10.1007/s00393-010-0623-3[Crossref]
• [28] Lorenc R., G’uszko P., Karczmarewicz E., Księżopolska-Orłowska K., Misiorowski W., Franek E., et al., Recommendations on the diagnosis and treatment of osteoporosis. Reducing the incidence of fractures through effective prevention and treatment., Terapia, 2007, XV,9, 3–51
• [29] Leslie W.D., Lix L.M., Langsetmo L., Berger C., Goltzman D., Hanley D.A., et al. Construction of a FRAX model for the assessment of fracture probability in Canada and implications for treatment, Osteoporosis Int, 2011,22,817–827 http://dx.doi.org/10.1007/s00198-010-1464-2[Crossref][WoS]
• [30] Kanis J.A., Borgstrom F., De Laet C., Johansson H., Johnell O., Jonsson B., et al., Assessment of fracture risk, Osteoporos Int, 2005, 16, 581–589 http://dx.doi.org/10.1007/s00198-004-1780-5[Crossref]
• [31] Bruyére O., Fossi M., Zegels B., Leonori L., Hilingsmann M. Neuprez A., Reginster J.Y., Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria, Rheumatol Int, (in press), DOI: 10.1007/s00296-012-2460-y [WoS][Crossref]
• [32] Crabtree N.J., Bebbington N.A., Chapman D.M., Wahid Y.S., Ayukt J., Boivin C.M., et al., Impact of UK National Guidelines based on FRAX - comparison with current clinical practice, Clinical Endocrinology, 2010, 73, 452–456 [WoS]
• [33] Bolland M.J., Grey A., Disparate outcomes from applying U.K. and U.S. osteoporosis treatment guidelines, J Clin Endocrinol Metab, 2010, 95, 1856–1860 http://dx.doi.org/10.1210/jc.2009-2157[Crossref]

Identyfikatory

DOI

10.2478/s11536-013-0205-2